Edwards Lifesciences Stock Slides as FTC Blocks $945M JenaValve Acquisition Trading Volume Ranks 380th

On August 6, 2025, Edwards Lifesciences (EW) fell 0.80%, with a trading volume of $310 million, ranking 380th in market activity. The stock’s decline coincided with the U.S. Federal Trade Commission’s (FTC) lawsuit to block its $945 million acquisition of JenaValve Technology Inc., a developer of transcatheter aortic valve replacement (TAVR-AR) devices. The FTC alleges the deal would eliminate direct competition in the TAVR-AR market, stifling innovation and increasing costs for patients. Edwards had previously acquired JC Medical in August 2024, consolidating its position in a sector where it now controls two of the only companies with ongoing U.S. clinical trials for TAVR-AR devices.

The FTC’s complaint argues that combining JenaValve and JC Medical under Edwards’ ownership would reduce market rivalry, potentially harming product quality and patient access. JenaValve’s Trilogy system is expected to seek FDA approval in late 2025, but the agency warns that the acquisition would delay or limit treatment options. Edwards disputes the claim, stating the deal would accelerate innovation and patient access. The company has revised its 2025 earnings guidance upward, citing minimal financial impact from the lawsuit, but the legal uncertainty remains a key risk for investors.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the role of liquidity concentration in short-term stock performance, particularly in volatile markets.